Literature DB >> 17885079

Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes.

Bridget S Wilkins1, Wendy N Erber, David Bareford, Georgina Buck, Keith Wheatley, Clare L East, Beverley Paul, Claire N Harrison, Anthony R Green, Peter J Campbell.   

Abstract

The role of histopathology in the diagnosis of essential thrombocythemia (ET) is controversial, and there has been little attempt to quantitate interobserver variability. Diagnostic bone marrow trephine biopsy specimens from 370 patients with ET by Polycythemia Vera Study Group (PVSG) criteria were assessed by 3 experienced hematopathologists for 16 different morphologic features and overall diagnosis according to the World Health Organization (WHO) classification. Our results show substantial interobserver variability, particularly for overall diagnosis and individual cellular characteristics such as megakaryocyte morphology. Reticulin grade was the dominant independent predictor of WHO diagnostic category for all 3 hematopathologists. Factor analysis identified 3 independent factors likely to reflect underlying biologic processes. One factor related to overall and lineage-specific cellularity and was significantly associated with JAK2 V617F status (P < .001), a second factor related to megakaryocyte clustering, and a third was associated with the fibrotic process. No differences could be discerned between patients labeled as having "prefibrotic myelofibrosis" or "true ET" in clinical and laboratory features at presentation, JAK2 status, survival, thrombosis, major hemorrhage, or myelofibrotic transformation. These results show that histologic criteria described in the WHO classification are difficult to apply reproducibly and question the validity of distinguishing true ET from prefibrotic myelofibrosis on the basis of subjective morphologic criteria. This study was registered at http://isrctn.org as #72251782 and at http://eudract.emea.europa.eu/ as #2004-000245-38.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17885079     DOI: 10.1182/blood-2007-05-091850

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  50 in total

1.  European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis. Haematologica 2012;97(3):360-5--comment.

Authors:  Jürgen Thiele; Attilio Orazi; Hans Michael Kvasnicka; Vito Franco; Emanuela Boveri; Umberto Gianelli; Heinz Gisslinger; Francesco Passamonti; Ayalew Tefferi; Tiziano Barbui
Journal:  Haematologica       Date:  2012-03       Impact factor: 9.941

Review 2.  Do we know more about essential thrombocythemia because of JAK2V617F?

Authors:  Claire Harrison
Journal:  Curr Hematol Malig Rep       Date:  2009-01       Impact factor: 3.952

Review 3.  Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms.

Authors:  Brady L Stein; Jason Gotlib; Murat Arcasoy; Marie Huong Nguyen; Neil Shah; Alison Moliterno; Catriona Jamieson; Daniel A Pollyea; Bart Scott; Martha Wadleigh; Ross Levine; Rami Komrokji; Rebecca Klisovic; Krishna Gundabolu; Patricia Kropf; Meir Wetzler; Stephen T Oh; Raul Ribeiro; Rita Paschal; Sanjay Mohan; Nikolai Podoltsev; Josef Prchal; Moshe Talpaz; David Snyder; Srdan Verstovsek; Ruben A Mesa
Journal:  J Natl Compr Canc Netw       Date:  2015-04       Impact factor: 11.908

Review 4.  WHO classification of myeloproliferative neoplasms (MPN): A critical update.

Authors:  Hans Michael Kvasnicka
Journal:  Curr Hematol Malig Rep       Date:  2013-12       Impact factor: 3.952

5.  Uses and abuses of JAK2 and MPL mutation tests in myeloproliferative neoplasms a paper from the 2010 William Beaumont hospital symposium on molecular pathology.

Authors:  Ayalew Tefferi; Pierre Noel; Curtis A Hanson
Journal:  J Mol Diagn       Date:  2011-06-30       Impact factor: 5.568

6.  Equivalence of BCSH and WHO diagnostic criteria for ET.

Authors:  C N Harrison; M F McMullin; A R Green; A J Mead
Journal:  Leukemia       Date:  2016-11-29       Impact factor: 11.528

7.  Multi-objective Parameter Auto-tuning for Tissue Image Segmentation Workflows.

Authors:  Luis F R Taveira; Tahsin Kurc; Alba C M A Melo; Jun Kong; Erich Bremer; Joel H Saltz; George Teodoro
Journal:  J Digit Imaging       Date:  2019-06       Impact factor: 4.056

Review 8.  [Myeloproliferative neoplasms: histopathological and molecular pathological diagnosis].

Authors:  K Hussein; G Büsche; J Schlue; U Lehmann; H Kreipe
Journal:  Pathologe       Date:  2012-11       Impact factor: 1.011

Review 9.  [Protein-dysregulation in human and murine myeloproliferative neoplasms].

Authors:  K Aumann
Journal:  Pathologe       Date:  2018-12       Impact factor: 1.011

Review 10.  Clinical potential of pacritinib in the treatment of myelofibrosis.

Authors:  Ana B Duenas-Perez; Adam J Mead
Journal:  Ther Adv Hematol       Date:  2015-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.